Elixir Pharmaceuticals (MM) (ELXR)

Elixir Pharmaceuticals, Inc. went out of business. Elixir Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and commercializes pharmaceuticals for the treatment of metabolic diseases. It develops small molecule drugs that mimic longevity responses, as well as used to treat a rang... Elixir Pharmaceuticals, Inc. went out of business. Elixir Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and commercializes pharmaceuticals for the treatment of metabolic diseases. It develops small molecule drugs that mimic longevity responses, as well as used to treat a range of age-related diseases, including diabetes and obesity. The company’s products include Metgluna and Glinsuna for the treatment of type 2 diabetes; Ghrelin, an oral antagonist for the treatment of metabolic diseases; and EX-1314, an oral drug developed for the treatment of type 1 diabetic gastroparesis. It has strategic alliances/partnerships with Kissei Pharmaceuticals, Bristol-Myers Squibb, Siena Biotech S.p.A., and Novartis Pharmaceuticals. The company was founded in 1999 and is headquartered in Cambridge, Massachusetts. 詳細を表示